European Heart Journal Advance Access originally published online on January 24, 2007
European Heart Journal 2007 28(3):334-344; doi:10.1093/eurheartj/ehl450
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome
1 Cardiovascular Research and Teaching Institute, OLV Hospital, Moorselbaan 164, 9300 Aalst, Belgium
2 Cardiovascular and Thoracic Surgery Department, Aalst, Belgium
3 Department of Clinical Epidemiology and Biostatistics, VU Medical Center, Amsterdam, Holland
Received 14 February 2006; revised 1 November 2006; accepted 30 November 2006; online publish-ahead-of-print 24 January 2007.
* Corresponding author. Tel: +32 53 72 4439; fax: +32 53 72 4185. E-mail address: andreasarkozy{at}yahoo.ca
Aims To analyse the follow-up data of implantable cardioverter-defibrillator (ICD) therapy in Brugada syndrome (BS).
Methods and results We conducted a retrospective, single centre study of 47 patients (mean age: 44.5 ± 15 years) with BS, who underwent primary prophylactic ICD implantation. All patients had baseline spontaneous (23 patients) or drug-induced (24 patients) coved type I ECG pattern. All patients were judged to be at high risk because of syncope (26 patients) and/or a positive family history of sudden death (26 patients). During a median follow-up of 47.5 months, seven patients had appropriate shocks. The presence of spontaneous type I ECG and non-sustained ventricular tachyarrhythmia in the ICD datalog suggested a trend towards shorter appropriate shock-free survival by Kaplan–Meier analysis (P = 0.037 and P = 0.012, respectively). Seventeen patients received inappropriate shocks (IS); eight patients for sinus tachycardia; six patients for new onset atrial arrhythmias; and five patients for noise oversensing. In multivariable Cox-regression analysis, new onset atrial fibrillation (AF) and less than 50 years of age were independent predictors of significantly shorter IS-free survival (P = 0.04 and P = 0.036, respectively).
Conclusion In high-risk patients with BS, primary prophylactic ICD therapy is an effective treatment. In this, young and otherwise healthy patient population, the IS rate is high.
Key Words: Brugada syndrome • Sudden death • ICD therapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Ding, W. Hua, H. Niu, K. Chen, and S. Zhang Primary prevention of sudden cardiac death using implantable cardioverter defibrillators Europace, September 1, 2008; 10(9): 1034 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons J. Am. Coll. Cardiol., May 27, 2008; 51(21): e1 - e62. [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons Circulation, May 27, 2008; 117(21): e350 - e408. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sarkozy, P. Brugada, L. Mont, and J. Brugada Optimizing the clinical use of implantable defibrillators in patients with Brugada syndrome Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I74 - I80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bonny, J. Tonet, G. Fontaine, and R. Frank Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome Eur. Heart J., November 2, 2007; 28(22): 2819 - 2820. [Full Text] [PDF]
|
|
|
|
|
|
S. Viskin and O. Rogowski Asymptomatic Brugada syndrome: a cardiac ticking time-bomb? Europace, September 1, 2007; 9(9): 707 - 710. [Full Text] [PDF]
|
|